Health Economics›Non-small cell lung cancer nonsquamous›Advanced or metastatic disease first-line elderly or poor performance status

Advanced or metastatic disease first-line elderly or poor performance status

Non-small cell lung cancer nonsquamous · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	—	7.5 mo	4	R 52 900 PFS proxy	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	7.5 mo	7	R 11 705 PFS proxy	1

2 of 2 regimens shown